Powering smarter drug development with precision PK/PD and bioanalysis
May 20, 2025
At Pharmidex, we help drug developers move faster and smarter with high-quality PK/PD assessments and bioanalytical services across a range of therapeutic areas.
🔬 Our team combines:
- Bespoke In vivo PK/PD & CNS penetration studies
- Wild-type, immunodeficient & humanised rodent models
- Advanced platforms: LC-MS/MS, qPCR, ELISA
🧠 Whether you're working on CNS drugs, oncology assets, or rare disease therapies, we deliver high quality data to drive confident decisions from lead optimisation to IND-enabling studies.
✨ Need to evaluate:
- BBB penetration?
- Target tissue exposure?
- PK profiling of small molecules or biologics?
We’ve got you covered.
📨 Let’s talk see how Pharmidex can support your next breakthrough:
🌐 www.pharmidex.com
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
